Advances in the field of genetic susceptibility to respiratory diseases (e.g. pulmonary fibrosis, emphysema, cystic fibrosis, pulmonary hypertension) have led pneumologists to integrate the familial risk dimension and work with genetics clinical teams and laboratories. Paradoxically, while thoracic oncologists look on a daily basis for acquired oncogenic alterations in non small cell lung cancer (NSCLC), they know little about inherited, genetic susceptibility to the disease. As a result, collaboration networks with clinical cancer geneticists are poorly developed in thoracic oncology. Faced with this observation, it seemed important to us to address this issue in a very practical way with this “Q and A on Hereditary Lung Cancer” editorial.